Cytek Biosciences director gets 4,629 shares at vesting
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cytek Biosciences, Inc. director Glenn P. Muir reported that 4,629 restricted stock units converted into 4,629 common shares on November 18, 2026. His direct common-stock holdings afterward were 7,715 shares; the reported post-transaction restricted-stock-unit balance was 47,840 units. The award’s shares vest over three years under the schedule described in the footnote.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F1, F2 | 4,629 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 4,629 | -- | -- |
Footnotes (2)
- F1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- F2. The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2026; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2027 and each August 18 thereafter.
Key Figures
Key Terms
RSU Award technical
contingent right technical
vest technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the CTKB RSU vesting schedule?
AI-generated analysis. How Rhea-AI works. Not financial advice.